Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843491 | 0.85 | BRD4 (0.58) | BRD4POLBKMT2ALMNACYP3A4 | |
| SCHEMBL12667142 | 0.82 | BRD4 (0.67) | BRD4POLBKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL30282498 | 0.82 | BRD4 (0.67) | BRD4POLBKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL28956225 | 0.82 | BRD4 (0.67) | BRD4POLBKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3824098 | 0.82 | POLB (0.66) | BRD4POLBMEN1KMT2ATDP1 | |
| SCHEMBL15042223 | 0.79 | BRD4 (0.63) | BRD4POLBKMT2ALMNAMAPT | |
| SCHEMBL1362127 | 0.79 | BRD4 (0.63) | BRD4KMT2ALMNACYP3A4CYP2C9 | |
| SCHEMBL3821889 | 0.79 | BRD4 (0.51) | BRD4POLBKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3823547 | 0.79 | BRD4 (0.51) | BRD4MEN1KMT2ALMNACYP3A4 | |
| SCHEMBL12368059 | 0.77 | BRD4 (0.59) | BRD4MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722589-B2 | Use of 1-alkyl-5-oxopyrrolidine-3-carboxylic esters as gas hydrate inhibitors with improved biodegradability | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-05-13 | — | — | US | disclosed |
| US-20130217892-A1 | Use Of N-Substituted 2-Pyrrolidone-4-Carboxylic Acid Esters And Solvents | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-08-22 | — | — | US | disclosed |
| US-20130217579-A1 | Pesticide Preparations Containing N-Substituted 2-Pyrrolidone-4-Carboxylic Acid Esters | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-08-22 | — | — | US | disclosed |
| US-20090042747-A1 | Use of 1-alkyl-5-oxopyrrolidine-3-carboxylic esters as gas hydrate inhibitors with improved biodegradability | CLARIANT INTERNATIONAL LTD. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217892-A1 | Use Of N-Substituted 2-Pyrrolidone-4-Carboxylic Acid Esters And Solvents | CACNA1B, C9, CACNA1E | BRD4 3472/4885POLB 566/4885MEN1 2122/4885 |
| US-20130217579-A1 | Pesticide Preparations Containing N-Substituted 2-Pyrrolidone-4-Carboxylic Acid Esters | DDT, PCCA, PC | BRD4 3135/4885POLB 3014/4885MEN1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.